{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:45:35Z","timestamp":1792701935569,"version":"4.5.0"},"reference-count":90,"publisher":"The Endocrine Society","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Complications of diabetes mellitus have significant impacts on morbidity, mortality, quality of life, and health costs for individuals. Setting and achieving glycemic targets to prevent these complications is a top priority when managing diabetes. However, patients often already have complications when diagnosed with diabetes mellitus. Therefore, methods to prevent disease progression become a crucial component of diabetes management. The purpose of this article is to review glycemic targets and methods of screening and managing diabetes-related complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Acquisition<\/jats:title>\n                  <jats:p>A PubMed review of the literature pertaining to diabetes mellitus, glycemic targets, microvascular complications, and macrovascular complications was conducted. We reviewed articles published between 1993 and 2024. Guidelines published by nationally recognized organizations in the fields of diabetes, nephrology, and cardiology were referenced. Public health statistics obtained by the Center for Disease Control and Prevention and the National Kidney Foundation were used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Evidence Synthesis<\/jats:title>\n                  <jats:p>Achieving glycemic targets and screening for diabetes-related complications at appropriate intervals remains the key factor for early detection and intervention. An algorithmic approach to glycemic management based on individual risk factors is beneficial in choosing pharmacotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The consequences of diabetes-related complications can be detrimental. However, achieving and maintaining glycemic targets combined with diligent screening, reduction of risk factors, and prompt treatment can halt disease progression.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae776","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:22:49Z","timestamp":1740500569000},"page":"S100-S111","source":"Crossref","is-referenced-by-count":15,"title":["Glycemic Targets and Prevention of Complications"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-6032","authenticated-orcid":false,"given":"Yumiko","family":"Tsushima","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospitals Cleveland Medical Center, Diabetes and Metabolic Care Center , Cleveland, OH 44106 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9391-0553","authenticated-orcid":false,"given":"Nicholas","family":"Galloway","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospitals Cleveland Medical Center, Diabetes and Metabolic Care Center , Cleveland, OH 44106 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"14","key":"2025022600530374100_dgae776-B1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"2025022600530374100_dgae776-B2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetes-related retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"issue":"9131","key":"2025022600530374100_dgae776-B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UKPDS Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"9131","key":"2025022600530374100_dgae776-B4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood glucose control with metformin on complication on overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UKPDS Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B5","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc24-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"2025022600530374100_dgae776-B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm-2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"2025022600530374100_dgae776-B7","author":"National Institute for Health and Care Excellence"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B8","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc24-S013","article-title":"13. Older adults: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"2025022600530374100_dgae776-B9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"issue":"24","key":"2025022600530374100_dgae776-B10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"The ADVANCE Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"2025022600530374100_dgae776-B11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"issue":"24","key":"2025022600530374100_dgae776-B12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"The Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"issue":"23","key":"2025022600530374100_dgae776-B13","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"issue":"10448","key":"2025022600530374100_dgae776-B14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomized controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"issue":"7258","key":"2025022600530374100_dgae776-B15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2025022600530374100_dgae776-B16","author":"Centers for Disease Control and Prevention"},{"issue":"10","key":"2025022600530374100_dgae776-B17","doi-asserted-by":"crossref","first-page":"e111320","DOI":"10.1371\/journal.pone.0111320","article-title":"Ten-year cumulative incidence of diabetes-related retinopathy. The Beijing Eye Study 2001\/2011","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"2025022600530374100_dgae776-B18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ophtha.2004.11.054","article-title":"Hyperglycemia, blood pressure, and the 9\u2013year incidence of diabetic retinopathy: the Barbados Eye Studies","volume":"112","author":"Leske","year":"2005","journal-title":"Ophthalmology"},{"issue":"6","key":"2025022600530374100_dgae776-B19","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/dc12-0790","article-title":"Predicting development of proliferative diabetic retinopathy","volume":"36","author":"Harris Nwanyanwu","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"2025022600530374100_dgae776-B20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ophtha.2009.06.051","article-title":"The 25-year incidence of visual impairment in type 1 diabetes mellitus the Wisconsin Epidemiologic Study of Diabetic Retinopathy","volume":"117","author":"Klein","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"2025022600530374100_dgae776-B21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1053\/ajkd.1998.v31.pm9631838","article-title":"Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM","volume":"31","author":"Estacio","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B22","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.2337\/dc24-S012","article-title":"12. Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"2025022600530374100_dgae776-B23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archophthalmol.2010.319","article-title":"Screening for presence or absence of diabetic retinopathy: a meta-analysis","volume":"129","author":"Bragge","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"2025022600530374100_dgae776-B24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jama.1993.03500100088034","article-title":"How effective are treatments for diabetic retinpathy?","volume":"269","author":"Ferris","year":"1993","journal-title":"JAMA"},{"issue":"1","key":"2025022600530374100_dgae776-B25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc20-1842","article-title":"Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes: the ACCORD trial","volume":"44","author":"Tang","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"2025022600530374100_dgae776-B26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.2337\/dc09-1941","article-title":"Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study","volume":"33","author":"Albers","year":"2010","journal-title":"Diabetes Care"},{"issue":"22","key":"2025022600530374100_dgae776-B27","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1161\/CIRCULATIONAHA.108.837369","article-title":"Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study (DCCT\/EDIC)","volume":"119","author":"Pop-Busui","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"2025022600530374100_dgae776-B28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc16-0081","article-title":"Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status","volume":"39","author":"Callaghan","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"2025022600530374100_dgae776-B29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/dc17-2062","article-title":"Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark","volume":"41","author":"Andersen","year":"2018","journal-title":"Diabetes Care"},{"key":"2025022600530374100_dgae776-B30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/DMSO.S37415","article-title":"Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey","volume":"6","author":"Sadosky","year":"2013","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025022600530374100_dgae776-B31","author":"National Kidney Foundation"},{"issue":"6","key":"2025022600530374100_dgae776-B32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B33","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.2337\/dc24-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"7","key":"2025022600530374100_dgae776-B34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamacardio.2021.0660","article-title":"Effect of dapagliflozin on cardiovascular outcomes according to baseline kidney function and albuminuria status in patients with type 2 diabetes a prespecified secondary analysis of a randomized clinical trial","volume":"6","author":"Zelniker","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10166","key":"2025022600530374100_dgae776-B35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trial","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"2025022600530374100_dgae776-B36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Heerington","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"2025022600530374100_dgae776-B37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patient with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"2025022600530374100_dgae776-B38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"10193","key":"2025022600530374100_dgae776-B39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"2025022600530374100_dgae776-B40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2025022600530374100_dgae776-B41","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2025022600530374100_dgae776-B42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2025022600530374100_dgae776-B43"},{"issue":"20","key":"2025022600530374100_dgae776-B44","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-Kidney-Metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"20","key":"2025022600530374100_dgae776-B45","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the scientific and clinical management of Cardiovascular-Kidney-Metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"21","key":"2025022600530374100_dgae776-B46","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"2025022600530374100_dgae776-B47","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2025022600530374100_dgae776-B48","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"2025022600530374100_dgae776-B49","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozn on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"issue":"9701","key":"2025022600530374100_dgae776-B50","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"2025022600530374100_dgae776-B51","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"2025022600530374100_dgae776-B52","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/dom.14465","article-title":"Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11","volume":"23","author":"Bonora","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2025022600530374100_dgae776-B53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B54","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.2337\/dc24-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"2025022600530374100_dgae776-B55","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International society of hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"issue":"33","key":"2025022600530374100_dgae776-B56","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"9","key":"2025022600530374100_dgae776-B57","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B58","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.2337\/dc24-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"19","key":"2025022600530374100_dgae776-B59","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1161\/CIR.0000000000000766","article-title":"Clinical management of stable coronary artery disease in type 2 diabetes mellitus: a scientific statement from the American Heart Association","volume":"141","author":"Arnold","year":"2020","journal-title":"Circulation"},{"issue":"25","key":"2025022600530374100_dgae776-B60","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"2025022600530374100_dgae776-B61","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm-2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"12","key":"2025022600530374100_dgae776-B62","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/dc19-0501","article-title":"Residual hypertriglyceridemia and estimated atherosclerotic cardiovascular disease risk by statin use in U.S. adults with diabetes: national health and nutrition examination survey 2007-2014","volume":"42","author":"Fan","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"2025022600530374100_dgae776-B63","first-page":"100","article-title":"Elevated triglyceride levels is independently associated with increased all-cause mortality in patients with established coronary heart disease","volume":"9","author":"Kelmpfner","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"2025022600530374100_dgae776-B64","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/dom.13537","article-title":"Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol","volume":"21","author":"Nichols","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2025022600530374100_dgae776-B65","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee","volume":"79","author":"Virani","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2025022600530374100_dgae776-B66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"9500","key":"2025022600530374100_dgae776-B67","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"2025022600530374100_dgae776-B68","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"2025022600530374100_dgae776-B69","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"2025022600530374100_dgae776-B70","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"2025022600530374100_dgae776-B71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with paropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"2025022600530374100_dgae776-B72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2022.03.025","article-title":"Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes","volume":"100","author":"de Vries","year":"2022","journal-title":"Eur J Int Med"},{"issue":"10","key":"2025022600530374100_dgae776-B73","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2025022600530374100_dgae776-B74","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition of metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"2025022600530374100_dgae776-B75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"issue":"5","key":"2025022600530374100_dgae776-B76","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"2025022600530374100_dgae776-B77","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"2025022600530374100_dgae776-B78","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"2025022600530374100_dgae776-B79","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc09-0148","article-title":"Histological course of nonalcoholic fatty liver disease in Japanese patients","volume":"33","author":"Hamaguchi","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"2025022600530374100_dgae776-B80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advance liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"2025022600530374100_dgae776-B81","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cld.2015.10.008","article-title":"Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease","volume":"20","author":"Hannah","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"8","key":"2025022600530374100_dgae776-B82","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2025022600530374100_dgae776-B83","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc23-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"10","key":"2025022600530374100_dgae776-B84","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American association of clinical endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"12","key":"2025022600530374100_dgae776-B85","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"2025022600530374100_dgae776-B86","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"2025022600530374100_dgae776-B87","doi-asserted-by":"crossref","first-page":"e2221","DOI":"10.1210\/clinem\/dgac034","article-title":"Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring","volume":"107","author":"Yapanis","year":"2022","journal-title":"J Clin Endocrnol Metab"},{"issue":"6","key":"2025022600530374100_dgae776-B88","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2337\/dc20-1690","article-title":"Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study","volume":"44","author":"Roussel","year":"2021","journal-title":"Diabetes Care"},{"issue":"7","key":"2025022600530374100_dgae776-B89","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00125-021-05437-z","article-title":"Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor na\u00efve controls","volume":"64","author":"Nathanson","year":"2021","journal-title":"Diabetologia"},{"issue":"2","key":"2025022600530374100_dgae776-B90","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-8587(22)00352-7","article-title":"Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24 month results from the randomized ALERTT1 trial","volume":"11","author":"Visser","year":"2023","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/Supplement_2\/S100\/62166964\/dgae776.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/Supplement_2\/S100\/62166964\/dgae776.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:53:24Z","timestamp":1740531204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/Supplement_2\/S100\/8042160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":90,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae776","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,25]]}}}